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The occurrence of coinfections in human African trypanosomiasis (HAT) patients was investigated using a retrospective data of
hospitalrecordsattheNationalSleepingSicknessReferralHospitalinAlupe,Kenya.Atotalof31patients,19malesand12females,
were diagnosed with HAT between the years 2000 and 2009. The observed co-infections included malaria (100%), helminthosis
(64.5%), typhoid (22.5%), urinary tract infections (16.1%), HIV (12.9%), and tuberculosis (3.2%). The species of helminthes
observed included Ancylostoma duodenale (38.7%), Ascaris lumbricoides (45.7%), Strongyloides stercoralis (9.7%), and Taenia spp.
(3.2%). The patients were also infected with Entamoeba spp. (32.3%) and Trichomonas hominis (22.6%) protozoan parasites. The
main clinical signs observed at the point of admission included headache (74.2%), fever (48.4%), sleep disorders (45.2%), and
general body pain (41.9%). The HAT patients were treated with suramin (early stage, 9/31) and melarsoprol (late stage, 22/31). In
conclusion, the study has shown that HAT patients have multiple co-infections which may inﬂuence the disease pathogenesis and
complicate management of HAT.
1.Introduction
Human African trypanosomiasis (HAT) is endemic in sub-
Saharan Africa, and at least 60 million people are at risk [1].
In Kenya, the disease is caused by Trypanosoma brucei rho-
desiense and occurs in the western part of the country. Prior
to 1990, most HAT cases originated from Lambwe Valley in
Nyanza Province, whereas, from 1990 to 2009, the majority
of cases came from new focus in Busia, Teso, and Bungoma
districts in Western Province [2]. The aggressive control
of the tsetse ﬂy vector by government and donor-funded
agencies and anthropogenic activities have caused a signif-
icant reduction in the number of HAT cases in Kenya, such
that, between 2000 and 2009, only 31 cases were reported
(Hospital data, Alupe subdistrict hospital, Kenya). However,
it should be noted that, for T.b. rhodesiense, there is wide-
spread underreporting due to poverty, misdiagnosis, and
mode of surveillance used [3].
HAT occurs in areas which are also endemic of other
tropical diseases, the main one being malaria. This is because
these diseases are vector transmitted, and the vectors (tsetse
ﬂies and mosquitoes) share the same habitat. Despite a wide
overlap between these diseases, published reports of coin-
fections are scarce in the literature. In East Africa, T.b.
rhodesiense is characterized by a wide spectrum of clinical
signs [4]. For ﬁrst-stage infections, the main clinical signs
and symptoms are not speciﬁc and include fever, headache,
body pains, loss of appetite, and enlarged lymph nodes. The
presence of a chancre at the site of tsetse bite may be indica-
tive for a trypanosome infection. Symptoms of second-stage
infections mainly include neuropsychiatric symptoms and
motorproblems.Inarecentstudy,79.7%oftheHATpatients
from Tanzania and 2.9% from Uganda had malaria [4]. The
investigators also showed that malaria and HIV coinfections
did not have any signiﬁcant implication on the clinical pres-
entation and treatment outcomes of T.b. rhodesiense infec-
tions. A similar study has not been undertaken in Kenya.
In sub-Saharan African countries, hospitals managing
HAT do not have a signiﬁcant mandate to tackle other trop-
ical diseases. In most cases, there is no policy as regards the2 Journal of Tropical Medicine
Table 1:PrevalenceofcoinfectionsinHATpatients(31)inNSSRH,
Alupe, Kenya, from 2000 to 2009.
Disease Number of patients Prevalence (%) ±
SE
Malaria 31 100
Helminthiasis 20 64.5 ±8
Ancylostoma duodenale 12 38.7 ±1
Strongyloides stercolaris 39 .7 ±5
Ascaris lumbricoides 14 45.2 ±8
Taenia spp. 1 3.2 ±3
Trichomonas hominis 72 2 .6 ±8
Entamoeba spp. 10 32.3 ±9
HIV-AIDS 4 12.9 ±4
Tuberculosis 1 3.2 ±3
Typhoid 7 22.6 ±8
Urinary tract infections 5 16.1 ±6
management of concurrent infections. This has also been at-
tributed to lack of accurate data on these coinfections [5].
Further, Rhodesian form of HAT is zoonotic, and it is not
clear cut as to whether the disease should be researched
and controlled by veterinary or medical authorities [5]. For
hospitals which have been earmarked to undertake research
and management of a single disease such HAT, recent decline
in the number of cases has reduced the workload of the
staﬀ, and this may lead to downgrading the disease from
“neglected” to simply being ignored [6]. Thus, it would be
important for these hospitals to handle multiple diseases.
Due to lack of accurate data on occurrence of these coin-
fections, their importance is not known. The current study
was aimed at establishing the infections which are associated
with HAT in Kenya. Further, the paper reviews literature of
HATcoinfectionsandtheirpossible implication onthepath-
ogenesis and management of respective diseases.
2.MaterialsandMethods
Retrospective data from National Sleeping Sickness Referral
Hospital (NSSRH) in Alupe, Kenya, were used in this study.
The patients are normally referred to the hospital by other
health centres or can report directly to the hospital once they
have signs associated with the disease. The hospital records
of the HAT patients were also examined for data on sex, age,
area of origin, parasites/coinfections, and disease stage. The
patients are normally screened for HAT and other tropical
diseases including malaria, typhoid, and helminthiasis using
standard parasitological methods. For HAT, the patients
underwent routine diagnosis as described by WHO [7].
Brieﬂy, blood obtained from the patients was ﬁrst checked
for the presence of trypanosomes using the direct wet
smear and capillary centrifugation technique methods. For
trypanosome negative specimens, the blood was injected
to Swiss white mice which were monitored for parasitemia
development. Disease stage determination was by examina-
tion of cerebrospinal ﬂuid (CSF) using the WHO criteria [7]
in which patients with trypanosomes in the CSF and/or a cell
count >5cells/mm3 were classiﬁed as late stage. The number
ofCSFwhitecellcountswasdeterminedbycountingthecells
using the Neubauer hemocytometer method.
Other diseases were diagnosed as described by Cheese-
brough[8].Malariadiagnosiswasbasedontheidentiﬁcation
of plasmodium on a thin blood ﬁlm and/or on a thick blood
ﬁlm stained with Giemsa [8]. Typhoid was diagnosed using
the Widal method [8]. Stool was also collected from the
patients and analysed for the presence of helminth eggs and
protozoa ova using wet smears stained with iodine. Blood
from patients with signs which could be attributed to human
immunodeﬁciency virus (HIV) was examined using ELISA
kits. Tuberculosis was diagnosed by sputum microscopy and
chest radiography.
Data was entered into Ms Excel, and descriptive statistics
werepreparedintermsoftablesandgraphs.Further,thedata
was exported to Ms Staview statistical package and analysed
todeterminethecorrelationsbetweentheoccurrenceofHAT
and other diseases.
3. Results
A total of 31 patients, 19 males and 12 females, were diag-
nosed with HAT between 2000 and 2009. The 31 HAT cases
were reported in 2000 (12), 2001 (7), 2002 (10), 2006 (1),
and 2009 (1). Two cases (6.4%) which had co-infection
with HIV resulted in death, while the rest were successfully
treated. The mean age of the patients was 32.5±2.3( r a n g e=
14–57), with the majority (72.4%) being less than 40 years
old. The patients which were in early and late stage were
9 (29%) and 22 (70%), respectively. The average period of
stay at the hospital was 40 (range = 13–63) days and was not
signiﬁcantly(P>0.05)associatedwithdiseasestage.Females
wereadmittedforaslightlylongertimethanmales(41versus
38 days), but the diﬀerence was not signiﬁcant (P = 0.44).
T h eH A Td r u g sw e r ep r o v i d e df o rf r e eb yW o r l dH e a l t h
Organization (WHO). The average cost for other treatment
requirements (including cost for hospital bed, food, and all
ailments except HAT) was Ksh 800 (11.4USD) per day. This
amounted to Ksh 32,000 (457USD) for the average 40 days
the patient spent at the hospital, and this was paid by the
Government of Kenya.
The number of coinfections is indicated in Table 1.I n
descending order the most common parasitic diseases in-
cluded malaria, helminthiasis, amoebiasis, and trichomoni-
asis. The commonest helminthes included Ascaris lumbri-
coides, Ancylostoma duodenale, Strongyloides stercoralis,a n d
Taenia spp. Other coinfections included typhoid, urinary
tract infection (UTI), human immunodeﬁciency virus-
acquired immune deﬁciency syndrome (HIV-AIDS) and tu-
berculosis. The most common coinfections consisted of
patients (29%) with a combination of with HAT, malaria,
helminth, and gastrointestinal protozoa (Table 2). Twenty-
six percent (26%) of the patients had combination of HAT
and malaria (Table 2).
Sex, age, and disease stage had no signiﬁcant eﬀects
(P>0.05) on types of coinfections found in the patients.Journal of Tropical Medicine 3
Table 2: Clinical signs observed in patients at the point of admis-
sion at NSSRH, Alupe, Kenya, from 2000 to 2009.
Signs Number of patients Percentage (%)
Headache 23 74.2
Fever 15 48.4
∗Sleep disorders (insomnia
and daytime sleepiness) 14 45.2
General malaise 13 41.9
Joint pains 8 25.8
Abdominal distension 7 22.6
∗Confusion 7 22.6
Pruritus 6 19.4
Nausea 6 19.4
Anorexia 6 19.4
Abdominal pain 6 19.4
Vomiting 5 16.1
General pain 5 16.1
Chest pain/congestion 5 16.1
Backache 4 12.9
∗Stiﬀ neck 4 12.9
∗Coma 4 12.9
Coughing 4 12.9
Diarrhoea 4 12.9
Oedema of body parts 3 9.7
Breathing diﬃculties 3 9.7
∗Lower limb
weakness/numbness 39 . 7
∗Restlessness 2 6.5
∗Muscle pain 2 6.5
Sacral wounds 2 6.5
∗Prostration 2 6.5
∗Stupor 2 6.5
Palpitation 2 6.5
Incontinence 2 6.5
∗Body chills 2 6.5
∗Paralysis 2 6.5
∗Dizziness 2 6.5
Dysuria 1 3.2
∗Lower limb pain 1 3.2
Chancre 1 3.2
Dehydration 1 3.2
∗Convulsions 1 3.2
∗Reduced libido 1 3.2
∗Late stage signs.
3.1. Clinical Signs Observed at the Point of Admission. The
meanhaemoglobin(Hb)levelsatadmissionandatdischarge
were 10.9 (SEM = 0.3) and 12g/dL (SEM = 0.5), respectively.
This showed that there was a signiﬁcant (P<0.05) im-
provement on Hb levels after treatment. Table 3 shows the
clinical signs observed in patients at the point of admission.
In descending order, the main clinical signs observed in the
Table 3: Pattern of coinfections in 31 HAT patients in NSSRH,
Alupe, Kenya, from 2000 to 2009.
Co-infection Frequency Percentage
HAT + malaria + helminth + GIT
protozoa 90 . 2 9
HAT + malaria 8 0.26
HAT + malaria + helminth 4 0.13
HAT + malaria + helminth + GIT
p r o t o z o a+U T I+t y p h o i d 20 . 0 6
HAT + malaria + helminth + GIT
protozoa + HIV 20 . 0 6
HAT + malaria + typhoid + UTI 2 0.06
HAT + malaria + TB + HIV 1 0.03
HAT + malaria + HIV + UTI +
typhoid 10 . 0 3
HAT + malaria + helminth + typhoid 1 0.03
HAT + malaria + helminth + GIT
protozoa + typhoid 10 . 0 3
HAT: human African trypanosomiasis, TB: tuberculosis, GIT: Gastro-intes-
tinal,UTI:urinarytractinfections,helminth:Ancylostomaduodenale,Stron-
gyloides stercolaris, Taenia spp, protozoa: Trichomonas hominis, Entamoeba
spp.
patients included headache (74.2%), fever (48.4%), sleep
disorders (45.2%), and general body pain (41.9%). The
clinical signs which could be associated with central nervous
system (CNS) involvement were observed in 21 patients
(67.7%) and included sleep disorders (insomnia and/or day
time sleep), stupor, paralysis, convulsions, and coma. There
were signiﬁcantly (P<0.05) more late-stage (86.3%) than
early-stage (22.2%) patients with CNS signs.
3.2. Drugs Administered to the Patients. Since the HAT cases
were due to T.b. rhodesiense, early-stage disease was treated
using 5 injections of suramin at a dosage of 20mg/kg body
weight (a maximum of 1g/injection) at intervals of 5–7
days, while late-stage disease was treated using Melarsoprol
(3.6mg/kg repeated every 7 days for 4 weeks). The main
type of drugs which were used to manage the coinfections
included trypanocidals, antimalarials, analgelsics, antiin-
ﬂammatory, antibiotics, dewormers, antihistamines, and an-
tiamoebas. The mean number of drug types given to the
patients was 5.5 (range = 3–9), with 74% of the patients
r e c e i v i n g5o rm o r ed r u gt y p e s .
4. Discussion
The current study reports the occurrence of 31 HAT cases
and the associated coinfections between 2000 and 2009. It is
important to note that most of the HAT cases were reported
between 2000 and 2002, with only 2 cases occurring between
2006 and 2010. Further, there is wide underreporting (69%)
[9]o fH A Tc a s e sd u et oT.b. rhodesiense, and, thus, there
could be other cases which were not addressed by the
referral hospital. The mean hospital stay per patient in the
current study was 40 days which is lower than that of
neighbouring Uganda (47 days) [1]. The treatment costs
(hospitalization and other non-HAT drugs) recorded in this4 Journal of Tropical Medicine
study were higher than those reported for other HAT studies
(120–147USDperpatient)[1,7].Thecostsinourstudywere
higher because of the high bed charges and occurrence of
coinfections which required multiple tests and subsequent
treatment drugs. However, it is imperative to note that the
costs for the HAT patients (average of 457USD) were catered
for by the Kenyan government—which can be compared
to the 6.5USD per capita available for healthcare in Kenya
[10]. There were more male than female patients, and this
is diﬀerent from what was reported for HAT due to T.b.
gambiense [11]. The reason for this scenario could not be
ascertained in the current study. As reported in other studies
[1,12],HA Tmainlyaﬀectspeoplethemostproductivegroup
(below 40 years), and this is diﬀerent for malaria where
children below 5 years are the most commonly aﬀected.
The clinical signs observed in the current study are com-
mon in sleeping sickness patients and mainly include head-
ache, sleeping disorders, fever, and general malaise amongst
others [4, 9, 13]. Headache is an unspeciﬁc and common
symptom amongst patients with HAT, and its frequency in
the current study was higher than reported for T.b. gam-
biense patients in other countries (79%) [13]. Further, the
prevalence of fever in the current study was higher than
that reported in T.b. gambiense patients [13, 14]. This could
be due to diﬀerences in the two trypanosome subspecies as
well as higher prevalence of malaria in the current study.
Sleeping disorders and other CNS manifestations were also
commoninthepatientsinthecurrentstudypossiblybecause
majority of them were in late-stage disease. The proportion
of patients in the current study which had sleeping disorders
was lower (45%) than that reported by Blum et al. [13]
(74%) but was higher than those reported by Burri et al. [15]
(29%) and Kuepfer et al. [4] (35%). In the late-stage HAT,
the disease causes a dysregulation of the circadian rhythm of
the sleep/wake cycle which is associated with insomnia and
episodes of daytime sleepiness [13].
Inspiteoftheimportanceofcoinfectionsinmanagement
of tropical diseases, little is known about their occurrence.
In most cases, HAT coinfections are only reported as case
studies [16, 17]o ra sa n e c d o t e s[ 1, 13]. The current study
showsthatthecommonestcoinfectionsinpatientswithHAT
include malaria and helminthosis. It is important to note
that all HAT patients were also infected with malaria which
reinforces the fact that the study area is highly endemic of
malaria. In comparison, Blum et al. [13] reported a malaria
prevalence of 50% in T.b. gambiense patients from several
endemic countries. In Tanzania and Sudan, malaria was
reported in 80% and 30% of the HAT patients, respectively
[4, 12]. In western Kenya, malaria is caused by P. falciparum
transmitted by culicine mosquitoes species that feed pri-
marily on humans and cattle [18]. Sleeping sickness in the
area is caused by T.b. rhodesiense,t r a n s m i t t e db yGlossina
pallidipes [19], and is zoonotic with animals such as cattle
and pigs being the main reservoir of the disease [20]. Since
the two diseases are coendemic, a combined control strategy
may include use of insecticide-treated nets, clearance of
the habitats harbouring the vectors, and spraying of live-
stock with acaricides. The strategies can employ existing
synergy from the local institutions such as nongovernmental
organizations (NGOs) and community-based organizations
(CBOs) which have control programs on malaria and HIV
[21].
Soil-transmitted parasites were also reported to be com-
mon amongst the HAT patients, with A. duodenale, A. lum-
bricoides,a n dS. stercolaris being the most commonly re-
portednematodes.AstudyinwesternKenyabyBrookeretal.
[22] found that 91.7% of children were infected with similar
range of helminths. Coinfections of T.b. gambiense and
helminths have been reported in humans [12, 17]. Although
thepathogenesisoftrypanosomesandhelminthcoinfections
have not been well studied in humans, animal model studies
have shown that the interaction could be either agonistic
and antagonistic depending on which of the parasites was
inoculated ﬁrst [23]. Infection with intestinal helminths was
shown to be protective against malaria severity [24, 25],
although this was disputed by other authors [26]. With their
propensity for serial sampling, animal models can be utilized
to determine the eﬀects of concurrent infections on the host
[23].
The occurrence of coinfections is bound to aﬀect the sus-
ceptibility and pathogenesis of the diseases involved. In the
currentstudy,theeﬀectsofthecoinfectionsontheimmunol-
ogy and hematology were not recorded, possibly due to the
fact the hospital was only equipped for standard diagnosis of
HAT. However, other studies have shown that HAT causes
severe changes including immunosuppression and haema-
tological disorders such as hemocytopenia and thrombocy-
topenia [1, 12, 27, 28]. Similar changes have been reported
for malaria [29], and thus a patient having both infections
might have poor prognosis. In case of further infection with
immunosuppressive diseases such as HIV, the patient might
have a fatal outcome, as what happened in the two cases
reported in this study. HIV is highly endemic in the study
area, where Busia District has the highest prevalence of HIV
in Kenya in 2002 [16, 30]. In the current study, the patients
were not routinely assessed for HIV, and thus it could not
be ascertained whether the other patients had the disease.
It would be important to determine the impact of HIV on
the occurrence of other neglected diseases such as HAT. In
recent years, HIV has been shown to increase the risk of
patients having leishmaniasis by 100- to 1000-fold [27] while
T.b. gambiense infection signiﬁcantly lowers the sensitivity of
HIV diagnostic tests [31].
At disease-management level, there is no clear guidance
regarding the management of coinfections such as malaria
and HAT. Thus, in HAT endemic areas the decision is left in
the hands of the clinician regarding the mode of treatment
[12]. In the current study, patients were treated with sev-
eral drugs to clear the coinfections, and the toxicological
implications of the consecutive use of these drugs on the
patients are not known. When used alone, drugs such as
suramin can cause complications while melarsoprol is con-
siderably toxic [32]. As observed by Matete and Kajejo [16],
the use of HAT drugs in patients having serious coinfections
such as malaria and HIV is bound to increase their level
of toxicities. For trypanostatic drugs such as eﬂornithine, a
competent immune system is required to clear the infec-
tion, and it has been noted that eﬂornithine cannot cureJournal of Tropical Medicine 5
HIV-positive, T.b. gambiense sleeping sickness patients [1,
33]. Further, melarsoprol was not curative in monkeys hav-
ing a co-infection of T.b. rhodesiense and natural simian im-
munodeﬁciency virus (SIV) [34], and this could have been
associated with immunosuppression caused by SIV. It would
be important to determine the impact of using drug com-
binations for these coinfections in terms of mechanisms
responsible for any toxicities and development of drug resis-
tance.
5. Conclusion
In conclusion, the retrospective study showed that malaria
and helminths are major coinfections found in patients hav-
ing HAT in Kenya. Combined control strategies targeting
these multiple diseases should be implemented. It would also
be important to carry out further studies in patients and
animal models to determine the impact of these coinfections
on the immunopathogenesis and management of HAT.
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